J&J has hypothesized that subcutaneous absorption of the drug may potentially enhance immune-mediated anticancer activity.

The FDA has approved the subcutaneous administration of a fixed combination of amivantamab (Rybrevant; Johnson & Johnson) and a recombinant human hyaluronidase for patients with non–small cell lung ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

The EGFR inhibitor's subcutaneous version heats up competition with AstraZeneca's Tagrisso in the front-line EGFR-mutated NSCLC space.

The FDA has approved the use of subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for use in all approved ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 ...

Breast cancer treatments are usually painful, time consuming and aggressive, which leads to long term hospitalization, medical staff and high economic expenses. To fight this problem there is a new ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Baxter International Inc. and Halozyme Therapeutics, Inc. today announced top-line results of a phase III study of HyQ, an investigational facilitated subcutaneous immune globulin (IG) product for use ...

The subcutaneous layer is the deepest skin layer. It protects a person’s body and keeps it warm. This layer also provides insulation and protection for vital tissues such as muscles, bones, and organs ...